Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Shares Gap Down on Analyst Downgrade

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)’s share price gapped down before the market opened on Tuesday after Jefferies Financial Group downgraded the stock from a moderate sell rating to a strong sell rating. The stock had previously closed at $24.59, but opened at $22.57. Fresenius Medical Care AG & Co. KGaA shares last traded at $23.0760, with a volume of 508,488 shares traded.

Several other equities research analysts have also recently weighed in on the company. Zacks Research cut Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Weiss Ratings lowered shares of Fresenius Medical Care AG & Co. KGaA from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 5th. Truist Financial set a $28.00 price target on shares of Fresenius Medical Care AG & Co. KGaA in a report on Monday, January 5th. Erste Group Bank cut shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. Finally, The Goldman Sachs Group downgraded Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a research report on Tuesday, January 20th. Five equities research analysts have rated the stock with a Hold rating and four have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average price target of $28.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Morgan Stanley grew its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 47.2% during the 4th quarter. Morgan Stanley now owns 2,939,839 shares of the company’s stock valued at $70,027,000 after purchasing an additional 942,497 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 279.7% during the second quarter. Bank of America Corp DE now owns 337,316 shares of the company’s stock valued at $9,637,000 after buying an additional 248,477 shares during the last quarter. ABC Arbitrage SA increased its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 1,136.0% in the fourth quarter. ABC Arbitrage SA now owns 249,800 shares of the company’s stock worth $5,950,000 after buying an additional 229,589 shares during the period. Integral Health Asset Management LLC increased its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 44.4% in the fourth quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock worth $15,483,000 after buying an additional 200,000 shares during the period. Finally, Pzena Investment Management LLC lifted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 1.0% in the 3rd quarter. Pzena Investment Management LLC now owns 14,816,852 shares of the company’s stock valued at $390,128,000 after acquiring an additional 153,870 shares during the last quarter. 8.37% of the stock is currently owned by institutional investors.

Fresenius Medical Care AG & Co. KGaA Price Performance

The firm has a fifty day moving average of $23.30 and a two-hundred day moving average of $24.46. The company has a current ratio of 1.36, a quick ratio of 1.00 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $13.57 billion, a PE ratio of 12.25, a PEG ratio of 0.72 and a beta of 0.90.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last announced its quarterly earnings results on Tuesday, February 24th. The company reported $0.83 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.16. The business had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $4.80 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 8.71% and a net margin of 5.03%. Research analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current fiscal year.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.